Orforglipron phase 3 trial results: what the data actually shows

What did @michaelalbertmd actually say?

Here's the awkward truth: the transcript submitted for this video is not medical commentary. The words captured appear to be song lyrics, not clinical analysis. So we're working from the caption, which makes four specific claims about the ATTAIN-1 phase 3 trial of orforglipron, an oral, non-peptide GLP-1 receptor agonist developed by Eli Lilly.

The caption states orforglipron produced 11.2% weight loss at 72 weeks with the highest dose versus 2.1% with placebo, that more than half of patients hit at least 10% weight loss, that one in five achieved 20% or more weight loss, and that the drug improved waist circumference. Those are specific, verifiable numbers, and they deserve a real look.

Does the science back this up?

Largely, yes, though context matters more than the caption lets on. The ATTAIN-1 trial data was presented at the American Diabetes Association Scientific Sessions in June 2025 and published in the New England Journal of Medicine. The headline numbers in the caption track with what was reported publicly by Lilly.

The 11.2% body weight reduction at 72 weeks with the highest dose (45 mg daily) versus placebo is consistent with what trial investigators reported. The threshold responder data, more than 50% achieving at least 10% loss and roughly 20% achieving at least 20% loss, also aligns with reported figures. These results are real. What the caption skips is that semaglutide 2.4 mg (Wegovy) delivered around 14.9% weight loss in the STEP 1 trial (Wilding et al., 2021, NEJM), and tirzepatide produced up to 20.9% in SURMOUNT-1 (Jastreboff et al., 2022, NEJM). Orforglipron's numbers are meaningful, but not best-in-class for weight loss.

What did they get wrong (or right)?

The caption gets the numbers right but earns partial credit at best. Calling orforglipron "the first oral non-peptide GLP-1" is accurate and actually significant. Every approved GLP-1 agonist to date is either injectable or, in the case of oral semaglutide (Rybelsus), a peptide formulation requiring strict fasting protocols and inconsistent absorption. Orforglipron is a small molecule, taken without food restrictions, which is a real practical difference for patients.

What the caption does not mention: the trial population matters. ATTAIN-1 enrolled adults with obesity or overweight without diabetes. We do not yet have long-term cardiovascular outcome data for orforglipron the way we do for semaglutide (SELECT trial, Lincoff et al., 2023, NEJM). The GI side effect profile, nausea, vomiting, diarrhea, was reportedly similar to other GLP-1 agents, and discontinuation rates due to adverse events were not discussed. Presenting responder rates without dropout context is a common way to make trial data look cleaner than it is.

What should you actually know?

Orforglipron is a genuinely interesting drug candidate. If it clears FDA review, it would be the first oral non-peptide GLP-1 agonist on the market, which removes a significant barrier for people who cannot or will not self-inject. That matters clinically and practically.

But "good results" in a phase 3 trial is not the same as approved, accessible, or proven over the long term. The drug is not yet FDA-approved as of mid-2025. There is no cardiovascular outcomes trial completed. And the weight loss numbers, while solid, sit below what injectable semaglutide and tirzepatide produce in head-to-head populations. For patients currently on compounded or brand GLP-1 therapies, this is a watch-and-wait development, not a reason to change anything. Anyone seeing this video and assuming orforglipron is available to them today is working with incomplete information.